Sunovion Pharmaceuticals said today that it plans to divest the U.S. market rights for its allergy and asthma products to Covis Pharma, in an effort to narrow its focus to the company’s COPD portfolio.
Included in the deal is Sunovion’s Alvesco inhalation aerosol, its Omnaris nasal spray and its Zetonna nasal aerosol. All three products are ciclesonides that are approved to treat either asthma or allergic rhinitis.
Get the full story at our sister site, Drug Delivery Business News.
The post Sunovion divests asthma, allergy tech to Covis Pharma appeared first on MassDevice.